NMS Labs Testing Helps to Enforce DEA Control of Synthetic Marijuana

Warning message

The subscription service is currently unavailable. Please try again later.

WILLOW GROVE, Pa.--(BUSINESS WIRE)--In an announcement last week, the U.S. Drug Enforcement Administration (DEA) placed the synthetic cannabinoid, MAB–CHMINACA (also known as ADB–CHMINACA), into Schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act. The same category as heroin and LSD, this announcement recognizes the risk presented by this drug and a level of concern about its effects.

“The synthetic cannabinoid marketplace continues to evolve at a breakneck speed, with new compounds appearing in treatment, Emergency Room, DUID arrest, and medical examiner populations every few weeks. Progressive companies concerned about safety in the workplace are also starting to add synthetic cannabinoid testing to pre-employment screens.”

The synthetic cannabinoid drug class, sometimes known as fake weed and sold under brand names such as “K2” and “Spice”, has been linked to an alarming increase in reports of illness, hospitalizations and even death in the United...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.